Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767105 | 0.88 | MAOB (0.58) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12010999 | 0.86 | MAOB (0.67) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1766880 | 0.82 | GYS1 (0.61) | MAOBMAOA | |
| SCHEMBL12533265 | 0.80 | MAOB (0.66) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2029459 | 0.79 | MAOB (0.49) | MAOBMAOAFFAR1 | |
| SCHEMBL31634183 | 0.79 | MAOB (0.61) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4342895 | 0.79 | MAOB (0.61) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1756377 | 0.78 | MRGPRX4 (0.65) | SMN1; SMN2 | |
| SCHEMBL17560021 | 0.77 | MAOB (0.70) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL810521 | 0.77 | MAOB (0.63) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011067174-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-02 | — | — | US | disclosed |
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-02 | — | — | US | disclosed |
| US-7939569-B1 | Aniline analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939569-B1 | Aniline analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, PYGL, GYS1 | MAOB 121/4885MAOA 93/4885ALDH1A1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.